Biohaven's Monthly Obesity Drug Doses Deliver 79% Myostatin Suppression In Interim Study
Weekly dosing reached 99% suppression, while the ongoing study will measure weight, fat and lean mass at week 24.
Biohaven, which develops treatments for immune diseases, neurological conditions and cancer, reported 79% myostatin suppression at week 12 with monthly doses of its experimental obesity drug taldefgrobep alfa Monday. The interim results, included in a presentation attached to its SEC filing, reached 99% with weekly treatment and support potential monthly dosing, the company said.
Monthly dosing meets a biological target
Taldefgrobep targets the myostatin-activin pathway involved in fat and muscle metabolism. Biohaven is pursuing a treatment that reduces fat while preserving or increasing lean muscle, delivered through an injection under the skin using an autoinjector.
The interim analysis found suppression of free myostatin across both dosing intervals. Biohaven said concentrations of the drug-myostatin complex were comparable between regimens and met or exceeded its targeted levels for inhibiting activin-receptor signaling.
The ongoing obesity study tests 150 mg every four weeks and 100 mg weekly against matching placebo groups. Its week-24 measures cover changes in total body weight, fat mass and lean mass—the clinical outcomes being tested alongside the biological response.
A blinded look at cholesterol
The mid-stage trial plans to randomly assign approximately 150 men and women ages 18 to 65 with overweight or obesity. Each active-treatment group is planned to include 50 participants, with 25 in each placebo group. Neither participants nor investigators know treatment assignments during the blinded treatment period.
The interim lipid analysis pooled drug and placebo recipients by dosing schedule, with 27 participants in the weekly group and 30 in the every-four-weeks group. One participant developed a grade-3 LDL cholesterol elevation and already had a grade-2 elevation at baseline.
The analysis recorded no treatment-emergent grade-2 through grade-4 elevations in total cholesterol or triglycerides. Biohaven said it identified no adverse lipid trends in the pooled interim readings.
Fat reduction and muscle preservation
Earlier work presented at ObesityWeek 2024 showed reduced fat and increased lean mass in obese mice given taldefgrobep alone or with semaglutide. Studies in healthy adults also tracked continued lean-mass increases and fat-mass decreases after dosing stopped.
Biohaven's presentation described a safety database spanning more than 700 treated trial participants, with repeat dosing studied for up to 192 consecutive weeks. The company characterized rates of gastrointestinal and muscle-related adverse events as low.
The obesity program is part of Biohaven's concentration on taldefgrobep, the epilepsy candidate opakalim, and protein-removing MoDE and TRAP treatments for immune-related diseases. Biohaven plans to add a group testing taldefgrobep with a GLP-1 drug to the ongoing obesity trial.
Biohaven expects topline results for both taldefgrobep alone and the planned GLP-1 combination in the second half of 2027.
Sources
- 8-K Filing — Biohaven Ltd. (BHVN) — SEC EDGAR
- Exhibit biohavencorporatepresent.htm — Biohaven Ltd. 8-K exhibit — SEC EDGAR